AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22307384 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg/day
Number of subjects: 179
Study 22307384 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide (both doses)
Number of subjects: 179
Study 22307384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initially) then switched to Teriflunomide
Number of subjects: 179
Study 20609215 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion (single day or five days, eight hours)
Number of subjects: 50
Study 20609215 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 50
Study 20609215 — intervention group
Group type: COMPARATOR
Intervention: Patients with systemic sclerosis
Number of subjects: 50
Study 20609215 — intervention group
Group type: COMPARATOR
Intervention: Patients with digital ulcers
Number of subjects: 50
Study 18048820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral minocycline
Number of subjects: 48
Study 18048820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 18048820 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tazarotene
Number of subjects: 48
Study 16211753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg orally, twice daily for 2.5 days)
Number of subjects: 9
Study 12106841 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler myocardial imaging (DMI)
Number of subjects: 5
Study 10758656 — intervention group
Group type: EXPERIMENTAL
Intervention: Momordica charantia (Karolla) extracts
Number of subjects: 100
Study 7726484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal pirodavir (2 mg per treatment) six times daily for 5 days
Number of subjects: 108
Study 7726484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal pirodavir
Number of subjects: 108
Study 7726484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 1974394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 micrograms/kg)
Number of subjects: 39
Study 1974394 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 39
Study 7343510 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reminiscing for forty-five minutes during each of five weeks
Number of subjects: 21
Study 7343510 — intervention group
Group type: COMPARATOR
Intervention: Focus on current life events (control group)
Number of subjects: 21
Study 7343510 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 21
Study 31665059 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely controlled mandibular positioner (RCMP) during polysomnography (PSG)
Number of subjects: 0
Study 31665059 — intervention group
Group type: EXPERIMENTAL
Intervention: DISE-assisted titration
Number of subjects: 0
Study 31665059 — intervention group
Group type: COMPARATOR
Intervention: Conventional subjective titration method
Number of subjects: 0
Study 28893675 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy
Number of subjects: 240
Study 28893675 — intervention group
Group type: COMPARATOR
Intervention: Non-opioid medication therapy
Number of subjects: 240
Study 26496285 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 40
Study 26496285 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP) + Low-Level Laser Therapy (LLLT)
Number of subjects: 40
Study 24612989 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-advertisement (animated web banner ad challenging front-of-package promotion)
Number of subjects: 1351
Study 24612989 — intervention group
Group type: COMPARATOR
Intervention: Control advertisement (animated web banner ad)
Number of subjects: 1351
Study 24612989 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-advertisement (misunderstood)
Number of subjects: 1351
Study 22619096 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic massage in addition to kinesiotherapy and physiotherapy
Number of subjects: 60
Study 22619096 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy and physiotherapy only
Number of subjects: 60
Study 19590518 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intracameral triamcinolone acetonide (TA)
Number of subjects: 120
Study 19590518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection of TA)
Number of subjects: 120
Study 16704874 — intervention group
Group type: EXPERIMENTAL
Intervention: <70% correction formula for mixing tests on aPTT
Number of subjects: 361
Study 16704874 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosner index for mixing tests on aPTT
Number of subjects: 361
Study 16704874 — intervention group
Group type: EXPERIMENTAL
Intervention: dPT mixing tests
Number of subjects: 361
Study 16704874 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosner index for mixing tests on dPT
Number of subjects: 361
Study 16704874 — intervention group
Group type: EXPERIMENTAL
Intervention: percent correction formula for mixing tests on dPT
Number of subjects: 361
Study 16328318 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939 (5 mg, 10 mg, 20 mg, 30 mg bid)
Number of subjects: 12
Study 16328318 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59-7939
Number of subjects: 12
Study 16328318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12034031 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) monotherapy
Number of subjects: 91
Study 12034031 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) plus ribavirin
Number of subjects: 91
Study 10449028 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Speed Protocol (PSP)
Number of subjects: 20
Study 10449028 — intervention group
Group type: COMPARATOR
Intervention: Progressive Incline Protocol (PIP)
Number of subjects: 20
Study 7817967 — intervention group
Group type: EXPERIMENTAL
Intervention: 125-nmol/m3 increment in particle-strong acidity for 12 hours
Number of subjects: 83
Study 7817967 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-ppb increment in ozone for 12 hours
Number of subjects: 83
Study 7817967 — intervention group
Group type: EXPERIMENTAL
Intervention: 125-nmol/m3 increment in particle-strong acidity for 12 hours among symptomatic children
Number of subjects: 83
Study 2193560 — intervention group
Group type: COMPARATOR
Intervention: Adenosine 3 mg
Number of subjects: 359
Study 2193560 — intervention group
Group type: COMPARATOR
Intervention: Adenosine 6 mg
Number of subjects: 359
Study 2193560 — intervention group
Group type: COMPARATOR
Intervention: Adenosine 9 mg
Number of subjects: 359
Study 2193560 — intervention group
Group type: COMPARATOR
Intervention: Adenosine 12 mg
Number of subjects: 359
Study 2193560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 2193560 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 6 mg followed by 12 mg if necessary
Number of subjects: 359
Study 2193560 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 5 mg followed by 7.5 mg if necessary
Number of subjects: 359
Study 6818806 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-4 mg of micronized oestradiol-17 beta taken orally
Number of subjects: 38
Study 6818806 — intervention group
Group type: COMPARATOR
Intervention: 3 mg of oestradiol-17 beta applied cutaneously
Number of subjects: 38
Study 6818806 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling of the oral dose from 2 mg to 4 mg
Number of subjects: 38
Study 31813087 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 1207
Study 31262379 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg every 4 weeks for 1 year
Number of subjects: 0
Study 31262379 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 1 year
Number of subjects: 0
Study 31262379 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 0
Study 28225996 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein as an add-on to metformin
Number of subjects: 12
Study 28225996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 25701295 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-coded prefilled medication syringes
Number of subjects: 10
Study 25701295 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication administration methods
Number of subjects: 10
Study 24835497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch
Number of subjects: 20
Study 24835497 — intervention group
Group type: COMPARATOR
Intervention: Injectable 1% lidocaine
Number of subjects: 20
Study 22709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of ocular diseases related to smoking
Number of subjects: 288
Study 22709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking patients if they smoke
Number of subjects: 288
Study 22709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Advising smoking patients to stop smoking
Number of subjects: 288
Study 22709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of resources for smoking cessation
Number of subjects: 288
Study 22709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly asking patients about smoking status
Number of subjects: 288
Study 22709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Advising patients to stop smoking if they smoke
Number of subjects: 288
Study 22709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of resources for smoking cessation
Number of subjects: 288
Study 22709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived competence in offering counselling
Number of subjects: 288
Study 22709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Main obstacle to smoking cessation counselling
Number of subjects: 288
Study 22709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in acquiring competencies in smoking cessation counselling
Number of subjects: 288
Study 18810388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrilube
Number of subjects: 40
Study 18810388 — intervention group
Group type: COMPARATOR
Intervention: Geliperm
Number of subjects: 40
Study 19717184 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban 0.035 mg/kg/h
Number of subjects: 3241
Study 19717184 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban 0.070 mg/kg/h
Number of subjects: 3241
Study 19717184 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban 0.105 mg/kg/h
Number of subjects: 3241
Study 19717184 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban 0.140 mg/kg/h
Number of subjects: 3241
Study 19717184 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban 0.175 mg/kg/h
Number of subjects: 3241
Study 19717184 — intervention group
Group type: COMPARATOR
Intervention: Control (unfractionated heparin + eptifibatide)
Number of subjects: 3241
Study 15942583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (bolus of 50 mg in priming solution, 1.0 mg/kg for the patient, followed by an infusion of 2.5 mg . kg(‐1) . h(‐1) until 15 minutes before the conclusion of cardiopulmonary bypass)
Number of subjects: 10
Study 15942583 — intervention group
Group type: COMPARATOR
Intervention: Cardiotomy suction
Number of subjects: 10
Study 12072621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 32
Study 12072621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9868121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 45
Study 9868121 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 45
Study 8194933 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitator model
Number of subjects: 91
Study 8194933 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational model
Number of subjects: 91
Study 8194933 — intervention group
Group type: COMPARATOR
Intervention: Routine Treatment
Number of subjects: 91
Study 3556133 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intravenous and oral Pentoxifylline with walk training
Number of subjects: 30
Study 3556133 — intervention group
Group type: COMPARATOR
Intervention: Walk training alone
Number of subjects: 30
Study 12036640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime 1 mg
Number of subjects: 90
Study 12036640 — intervention group
Group type: COMPARATOR
Intervention: Control (nonadministration of intracameral antibiotic prophylaxis)
Number of subjects: 90
Study 12036640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 90
Study 31466895 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS laparoscopic appendectomy
Number of subjects: 37
Study 31466895 — intervention group
Group type: COMPARATOR
Intervention: Video of laparoscopic appendectomy
Number of subjects: 37
Study 30312309 — intervention group
Group type: EXPERIMENTAL
Intervention: Health post (HP) based intervention arm
Number of subjects: 282
Study 30312309 — intervention group
Group type: EXPERIMENTAL
Intervention: Health center (HC) based intervention arm
Number of subjects: 282
Study 30312309 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 282
Study 27504403 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Loop molar distalization
Number of subjects: 30
Study 27504403 — intervention group
Group type: COMPARATOR
Intervention: Pendulum appliance
Number of subjects: 30
Study 24560365 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) at 0.2mg/kg bodyweight
Number of subjects: 500
Study 24560365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) at 0.2mg/kg bodyweight
Number of subjects: 500
Study 24560365 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (LEV) at 7.5mg/kg bodyweight
Number of subjects: 500
Study 24560365 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzimidazole (BZ) at 3.75-5mg/kg bodyweight
Number of subjects: 500
Study 24560365 — intervention group
Group type: EXPERIMENTAL
Intervention: Netobimin (NET) at 7.5mg/kg bodyweight
Number of subjects: 500
Study 24560365 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 500
Study 24560365 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-drug resistance (MDR) identified
Number of subjects: 500
Study 22366293 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin regimen A
Number of subjects: 67
Study 22366293 — intervention group
Group type: COMPARATOR
Intervention: Insulin regimen B
Number of subjects: 67
Study 20369095 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (bar) - splinted mini-implants inserted using a prefabricated stainless steel guide
Number of subjects: 45
Study 20369095 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (ball) - splinted mini-implants placed without a guide
Number of subjects: 45
Study 18380825 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of i.v. furosemide
Number of subjects: 62
Study 18380825 — intervention group
Group type: COMPARATOR
Intervention: Oral fluids only (control)
Number of subjects: 62
Study 16280073 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopur (subcutaneous, SC)
Number of subjects: 125
Study 16280073 — intervention group
Group type: COMPARATOR
Intervention: Repronex (subcutaneous, SC)
Number of subjects: 125
Study 12371576 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Empowerment Intervention (FEI) - three one-hour, home-based meetings per week for approximately 10 weeks from a clinician-trained paraprofessional.
Number of subjects: 0
Study 12371576 — intervention group
Group type: COMPARATOR
Intervention: Extended Services Intervention (ESI) - monthly phone contacts and referral information as needed.
Number of subjects: 0
Study 10589001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.16 ppm ozone for 7.6 hours
Number of subjects: 9
Study 10589001 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 9
Study 8668558 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in mealtime context and mealtime interactions
Number of subjects: 0
Study 8668558 — intervention group
Group type: EXPERIMENTAL
Intervention: Field experimentation in nursing
Number of subjects: 0
Study 1836339 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump (CP, Biomedicus)
Number of subjects: 50
Study 1836339 — intervention group
Group type: COMPARATOR
Intervention: Roller pump (RP, Stöckert)
Number of subjects: 50
Study 7055527 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg (male) / Diazepam 10 mg (female) via Z-track injection technique
Number of subjects: 185
Study 7055527 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 100 mg i.m.
Number of subjects: 185
Study 7055527 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam via Z-track injection technique
Number of subjects: 185
Study 7055527 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam via other injection techniques (not specified)
Number of subjects: 185
Study 30644827 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin bleached with 10% carbamide peroxide (CP) (at-home bleaching)
Number of subjects: 30
Study 30644827 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin bleached with 35% hydrogen peroxide (HP) (in-office bleaching)
Number of subjects: 30
Study 30644827 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 30
Study 28017916 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light smartphone use
Number of subjects: 22
Study 28017916 — intervention group
Group type: COMPARATOR
Intervention: Conventional LED smartphone use
Number of subjects: 22
Study 27206905 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 1053
Study 27206905 — intervention group
Group type: COMPARATOR
Intervention: iDMT
Number of subjects: 1053
Study 25153538 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib (300-900 mg twice a day)
Number of subjects: 47
Study 25153538 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib (300-600 mg twice a day)
Number of subjects: 47
Study 25153538 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib (900 mg twice a day)
Number of subjects: 47
Study 25153538 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib (not specified dose)
Number of subjects: 47
Study 22579443 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic wound retractor
Number of subjects: 250
Study 20933178 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.2 mg/kg per day, reached at 3 weeks)
Number of subjects: 48
Study 20933178 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 48
Study 17657599 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg once daily
Number of subjects: 333
Study 17657599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 15866769 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for elevated blood lead concentrations (20-44 microg/dL)
Number of subjects: 0
Study 11401051 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant nasal symptoms (blocked nose, sneezing, nasal discharge, thick yellow nasal discharge)
Number of subjects: 8469
Study 11401051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal symptoms
Number of subjects: 8469
Study 11401051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal symptoms due to exposure to animals
Number of subjects: 8469
Study 11401051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal symptoms due to damp/cold air
Number of subjects: 8469
Study 9728588 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with concurrent radiation therapy
Number of subjects: 0
Study 9728588 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and vinblastine as induction chemotherapy
Number of subjects: 0
Study 8067834 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 60
Study 8067834 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 60
Study 3051878 — intervention group
Group type: EXPERIMENTAL
Intervention: N alpha-triglycyl-lysine vasopressin
Number of subjects: 71
Study 3051878 — intervention group
Group type: COMPARATOR
Intervention: Lysine vasopressin
Number of subjects: 71
Study 31390349 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief relaxation intervention plus verbal suggestions
Number of subjects: 120
Study 31390349 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief relaxation intervention only
Number of subjects: 120
Study 31390349 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal suggestions only
Number of subjects: 120
Study 31390349 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study 28874797 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + Cet
Number of subjects: 104
Study 28874797 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 104
Study 28874797 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + Cet + Bev
Number of subjects: 104
Study 28874797 — intervention group
Group type: COMPARATOR
Intervention: CT + Bev
Number of subjects: 104
Study 26448264 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 2, 4, 8, or 12 mg
Number of subjects: 1480
Study 26448264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1480
Study 26448264 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 1480
Study 23596815 — intervention group
Group type: EXPERIMENTAL
Intervention: Periplaneta americana extract plus conventional medication for sepsis
Number of subjects: 66
Study 23596815 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 66
Study 21312348 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team care program (12 weeks, 1 day per week; individual treatments, group exercises, and group education)
Number of subjects: 53
Study 21312348 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient care
Number of subjects: 53
Study 19416227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 568
Study 19416227 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone 0.005% ointment
Number of subjects: 568
Study 17161948 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult cognitive task
Number of subjects: 0
Study 17161948 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy cognitive task
Number of subjects: 0